Fig. 6: GSK602 enhances the antitumor effect of imatinib in vivo. | Cell Death & Disease

Fig. 6: GSK602 enhances the antitumor effect of imatinib in vivo.

From: RETRACTED ARTICLE: BRD9 inhibition promotes PUMA-dependent apoptosis and augments the effect of imatinib in gastrointestinal stromal tumors

Fig. 6

A Nude mice were injected s.c. with 5 × 106 WT or PUMA-KO GIST-882 cells. After 7 days, mice were treated with 2 mg/kg GSK602 daily, 50 mg/kg imatinib, or their combination for 10 consecutive days. Tumor volume at indicated time points after treatment was calculated and plotted with p values for indicated comparisons, n = 6 in each group. B Mice weight after treatment. C Mice with WT or PUMA-KO GIST-882 xenograft tumors were treated with 2 mg/kg GSK602, 50 mg/kg imatinib, or their combination as in (A) for 4 consecutive days. Paraffin-embedded sections were analyzed by TUNEL staining. TUNEL-positive cells were counted and plotted. D Tissue sections from (C) were analyzed by cleaved caspase 3 staining. Cleaved caspase 3-positive cells were counted and plotted. Results were expressed as means ± SD of three independent experiments. *P < 0.05; **P < 0.01.

Back to article page